CDK4 and prostate carcinoma: The hypothesis of this study was that palbociclib would improve clinical outcomes, given the preclinical data supporting the use of CDK4/6 inhibitors in prostate cancer detailed above and the anticipated parallels between prostate cancer and breast cancer where clinical benefit has been clearly established.